SCHEMBL22498087

SCHEMBL22498087

C1CCCN(CCSC2=NCCN2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.49
▸ ALOX15 P16050 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ TSHR P16473 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10725688 1.00 ALDH1A1 (0.49) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL10728227 0.98 ALDH1A1 (0.47) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
SCHEMBL10728546 0.98 ALDH1A1 (0.50) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL10730479 0.97 ALDH1A1 (0.49) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
SCHEMBL25369656 0.93 ALOX15 (0.43) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
SCHEMBL25366474 0.93 ALOX15 (0.43) ALDH1A1ALOX15HRH3MAPTSMN1; SMN2
SCHEMBL25366774 0.92 ALDH1A1 (0.42) ALDH1A1ALOX15HRH3MAPTLMNA
SCHEMBL25367412 0.90 ALDH1A1 (0.46) ALDH1A1HRH3MAPTSMN1; SMN2GLA
SCHEMBL25365932 0.90 ALDH1A1 (0.46) ALDH1A1HRH3MAPTSMN1; SMN2GLA
SCHEMBL25364232 0.90 ALOX15 (0.41) ALDH1A1ALOX15HRH3MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 — — US claimed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 — — CN claimed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 — — EP claimed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 — — WO claimed
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 — — US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 — — CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 — — EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 — — WO disclosed
EP-3947394-A1 IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS Université de Paris (FR) 2022-02-09 — — EP disclosed
WO-2020201096-A1 IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS Université de Paris (FR) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 ALDH1A1 2260/4885ALOX15 3070/4885HRH3 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback